107 results about "Diagnostic biomarker" patented technology

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

The application belongs to the field of biochemical detection, and specifically discloses a new use of a GPR18 and other gene detection agent combination and a depression detection reagent. The application of the GPR18 expression level detection agent in the preparation of a major depressive disorder detection product. The expression amount of GPR18, PDK4, NRG1 and EPHB2 in the application actually has high diagnostic efficiency, and can be used as an independent candidate diagnostic biomarker. The accuracy of each as a screening indicator reaches 0.6 to 0.8, reaching the standard of a medium-strength screening indicator, and the accuracy of the combined expression amount indicator as a screening indicator reaches 0.779.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

The invention belongs to the technical field of medical detection, and particularly relates to a marker for smoke disease diagnosis and application thereof. The invention discloses a marker for smoke disease diagnosis. The marker for smoke disease diagnosis is miRNA (micro Ribonucleic Acid); the miRNA is hsa-miR-4433a-5p, and the nucleotide sequence of the miRNA is as shown in SEQ ID NO. 1 (sequence identifier number 1). Experiments prove that the expression level of hsa-miR-4433a-5p in smoke disease patients is obviously higher than that of hsa-miR-4433a-5p in healthy people, and hsa-miR-4433a-5p can be used as a marker for smoke disease diagnosis. Meanwhile, the marker for smoke disease diagnosis is applied to preparation of the kit, the content of hsa-miR-4433a-5p in serum can be detected through a real-time fluorescent quantitative PCR technology, and the kit has the advantages of being high in sensitivity and accuracy and wide in application prospect.

This invention discloses a lncRNA biomarker associated with AML, characterized in that the lncRNA biomarker is lncRNA FOXN3-AS1, and the nucleotide sequence of lncRNA FOXN3-AS1 is shown in SEQ ID NO: 1. This invention also discloses the application of a detection kit and method in the diagnosis and prognosis of AML. The lncRNA FOXN3-AS1 of this invention, as an auxiliary diagnostic biomarker for clinical detection of AML, has the advantages of simple operation, low cost, and accurate detection, making it suitable for clinical screening. The biomarker provided by this invention can be applied to the preparation of early AML assessment products, which is beneficial for further elucidating the pathogenesis of AML and helps in the discovery of novel small molecule drug targets with potential therapeutic value.

The application relates to a blood biomarker for evaluating and diagnosing Parkinson's disease and an application thereof. The blood biomarker is SERPINA3 and / or alpha-Syn. By using the biomarker as a diagnostic biomarker for Parkinson's disease, early diagnosis of Parkinson's disease can be assisted by detecting the SERPINA3 level and the alpha-Syn level in a blood sample, the trauma is small, the operation is simple, and the method is suitable for most patients and has high patient acceptance; and the SERPINA3 and alpha-Syn levels in the blood sample can be determined by a photochemical luminescence detection method, the detection sensitivity is high, the accuracy is high, and early, efficient and high-precision diagnosis of Parkinson's disease can be realized.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

This invention discloses the application of ESCO1 and NUFIP2 in the diagnosis and treatment of pancreatic cancer, relating to the field of biomedical technology. This invention provides the application of ESCO1 and / or NUFIP2 as pancreatic cancer biomarkers in the preparation of pancreatic cancer diagnostic or prognostic assessment products, and also provides the application of ESCO1 and / or NUFIP2 as drug targets in the screening or preparation of drugs for the prevention and / or treatment of pancreatic cancer. This invention discovers that ESCO1 and NUFIP2 have important biological significance in pancreatic cancer, with NUFIP2 expression regulated by ESCO1, and both expression levels positively correlated with the malignant progression of pancreatic cancer. Therefore, ESCO1 and NUFIP2 can not only serve as potential diagnostic biomarkers and therapeutic targets for pancreatic cancer, but also provide new theoretical basis and research directions for optimizing pancreatic cancer immunotherapy strategies.

The application discloses use of LncRNA00_178, miR-466b-3p and Gucy1b1 as acute lung injury markers or drug targets, and belongs to the technical field of biomarkers and drug targets. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, a miR-466b-3p down-regulator can be used to prepare a pharmaceutical composition for preventing and treating acute lung injury, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The application has the beneficial effects that the application proposes that LncRNA00_178 and miR-466b-3p, and miR-466b-3p and Gucy1b1 have a target binding relationship. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, the silence of miR-466b-3p inhibits LPS-induced apoptosis of alveolar epithelial cells, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The data provide new insights for the treatment mechanism of ALI and the identification of specific targets, and provide a new idea for the research and development of new drugs for acute lung injury, and have a wide application prospect.

The present application describes miRNAs in the diagnosis and treatment of small fiber neuropathy (SFN).

The invention belongs to the technical field of biomarkers, and particularly relates to a marker for unexplained recurrent spontaneous abortion and application of the marker. The marker is at least one of LARP1, LSM1 and NCBP2 (National Center For Biotechnology Protein). The invention has the following beneficial effects: the expression of six m7G regulatory factors in URSA is abnormal: LSM1 and NUDT16 are up-regulated, and IFIT5, LARP1, NCBP2 and NUDT4 are down-regulated (P < lt >; 0.05). Machine learning determines that LSM1, LARP1 and NCBP2 are high-performance diagnostic biomarkers, and the diagnostic values of the high-performance diagnostic biomarkers are verified by qRT-PCR and immunofluorescence in independent samples.

The invention discloses a circular non-coding RNA (Ribonucleic Acid) molecule circSENP6 and application thereof. The nucleotide sequence of the circSENP6 is shown as SEQ ID NO. 1. The invention also discloses a preparation method of the circular non-coding RNA molecule circSENP6. The circular non-coding RNA molecule circSENP6 can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can be used for early discovering coronary heart disease patients, reducing the death rate of coronary heart disease and improving the prognosis of patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

The application discloses a circRNA detection method based on Argonaute protein and rolling circle amplification. The method comprises the following steps: mixing a sample containing target circRNA to be detected with a specific reverse transcription primer and reverse transcriptase to obtain long-chain cDNA; mixing the obtained long-chain cDNA with pfAgo, gDNA and a DNA nucleic acid probe to carry out a reaction, and calculating the content of the target circRNA according to the fluorescence signal of the reaction mixture; the nucleotide sequence of the gDNA is specifically complementary to the cDNA sequence obtained by reverse transcription of the circRNA; the sequence of the DNA nucleic acid probe is specifically complementary to the sequence of the cDNA after one cutting of the cDNA by the pfAgo; and the DNA nucleic acid probe is a single-stranded DNA probe with a fluorescent label. The application can realize high-sensitivity, high-specificity and multiple target simultaneous analysis and detection of potential diagnostic biomarkers of liver cancer such as hsa_circ_0001445 and hsa_circ_0001141.

The instant disclosure relates to methods of treating sepsis by administering emapalumab. Also provided are diagnostic biomarkers for sepsis.

According to the application of the plasma exosome circRNA to the biomarker for early diagnosis of the lung adenocarcinoma, the plasma exosome marker circRNA is annular hsacirc0033861, hsacirc0043273 and hsacirc0011959, and the plasma exosome circRNA can be used as a biomarker for early diagnosis of the lung adenocarcinoma. The method comprises the following steps: firstly, constructing a circRNA / lncRNA-miRNA-mRNA regulation and control network in the plasma exosome on the basis of ceRNA microarray data and miRNA sequencing data of the exosome of a lung adenocarcinoma patient; according to the present invention, the lung adenocarcinoma patient specific plasma exosome with significant difference is screened by using a bioinformatics method so as to be adopted as the diagnosis marker, verification is performed in the lung adenocarcinoma patient through the reverse transcription real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), and the hsacirc0033861, the hsacirc0043273 and the hsacirc0011959 are finally screened, and can be used as the lung adenocarcinoma early diagnosis marker.

The invention discloses a circular non-coding RNA molecule hascirc0000799, which can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can find coronary heart disease patients at an early stage, reduce the death rate of the coronary heart disease and improve the prognosis of the patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

The invention discloses a tsRNA-SecTCA-L35 molecule and application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a colorectal cancer treatment target, and relates to the technical field of biological medicine. The invention provides application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a treatment target, in the diagnosis level, the molecule as a novel biomarker can be sensitively and specifically detected in samples such as plasma and tissue through qRT-PCR and other technologies, a brand new tool is provided for early discovery and non-invasive diagnosis of colorectal cancer, and the application of the tsRNA-SecTCA-L35 molecule as the colorectal cancer diagnosis biomarker and the treatment target is wide. In the aspect of treatment, by designing an analogue related to the molecular function and preparing the analogue into a pharmaceutical composition of a carrier such as lipidosome, the expression of the analogue in tumor cells can be effectively up-regulated, so that the proliferation of cancer cells is remarkably inhibited in vivo and in vitro, the death of the cancer cells is promoted, and the definite anti-tumor activity is shown; the important clinical application value is realized.

The invention belongs to the field of biological medicine, and particularly relates to a biomarker for clinical diagnosis of high-risk neuroblastoma and application of the biomarker. A product capable of being used for clinical diagnosis of high-risk neuroblastoma comprises a reagent for detecting the expression level of a biomarker, and the biomarker is plasma exosome protein CHD1. By detecting the CHD1 expression level, existing clinical indexes can be supplemented, precise layering and precise treatment of neuroblastoma are achieved, and meanwhile the kit has important guiding significance for prognosis judgment of tumor children.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

This invention belongs to the field of biomedical technology, specifically relating to the application of plasma exosome biomarkers in the diagnosis and early warning of diabetic bladder dysfunction. This invention pioneered the use of 4D-DIA proteomics technology to conduct a comprehensive differential analysis of plasma exosome proteins from patients with diabetic bladder dysfunction (DBD). It successfully identified protein components with significantly different expression levels in the plasma exosomes of DBD patients, demonstrating significant value as potential diagnostic biomarkers. This invention is the first to propose that the detection of a four-protein combination in plasma exosomes (FCGR3B+THBS1+HLA-F+ATP5PB) can serve as a biomarker for diabetic bladder dysfunction (DBD) and also as an early warning indicator for the disease. This protein combination achieved an overall accuracy of 83.3% in identifying DBD.

This invention discloses a biomarker composition, product, and application for lung cancer detection or diagnosis, relating to the field of lung cancer diagnostic technology. The biomarker composition provided by this invention has the advantages of high specificity and high sensitivity; 100% specificity means a zero false positive rate, avoiding unnecessary anxiety, unnecessary radiation exposure, and further invasive examinations. Based on the lung cancer detection or diagnostic biomarker composition provided by this invention, lung cancer diagnostic products, such as reagents, kits, chips, hybridization probes, or sequencing libraries, can be further developed. This will help achieve rapid, highly sensitive, and highly specific detection or diagnosis of lung cancer.

This invention relates to the field of biomedical technology and discloses a biomarker for diagnosing polycystic ovary syndrome (PCOS) and its application. The diagnostic biomarker is circSPECC1(4), which is formed by reverse splicing and circularization of the fourth exon of the SPECCC1 gene. It has a length of 1580 nt and possesses a closed circular RNA structure. circSPECC1(4) is specifically highly expressed in ovarian granulosa cells of PCOS patients, and there is no significant difference in the mRNA expression level of its parent gene SPECCC1. circSPECC1(4) possesses RNase R nuclease resistance stability and is mainly located in the cytoplasm. Knocking down the expression of circSPECC1(4) can significantly promote apoptosis of ovarian granulosa cells and arrest the ovarian granulosa cell cycle at the G0 / G1 phase. This invention clearly demonstrates that circSPECC1(4) can serve as a specific diagnostic biomarker for PCOS, fully verifying the structural characteristics, expression specificity, and pathological regulatory function of this circular RNA, filling the gap in the existing field of PCOS diagnosis which lacks highly specific and stable molecular diagnostic targets.

The invention discloses application of PYGL as an auxiliary diagnosis marker for hepatitis E related acute hepatic failure, and belongs to the technical field of biomedical detection. By detecting the expression level of PYGL in serum of a subject, hepatitis E related acute hepatic failure patients (HEV-ALF), acute hepatitis E patients (AHE) and healthy control people (HCs) can be effectively distinguished. The result shows that the serum PYGL expression level of HEV-ALF patients is obviously higher than that of acute hepatitis E patients and healthy control people; the serum PYGL expression level has significant correlation with the clinical outcome of patients with hepatitis E related acute hepatic failure, and the serum PYGL expression level of patients in a death group is significantly higher than that of patients in a survival group; the expression level of the serum PYGL is also associated with the number of organ failure of the patient, and can reflect the dynamic change of the condition of the patient. Therefore, the serum PYGL can be used as an effective biomarker for auxiliary diagnosis of the hepatitis E related acute hepatic failure and prognosis evaluation of the hepatitis E related acute hepatic failure.

The invention relates to application of a myocardial injury marker RSPO1 in preparation of a product for identifying cardiovascular diseases. The invention evaluates the expression profiles of all LGR4 ligands under cardiovascular diseases at present, provides the application of RSPO1 as a potential drug target, and further provides the application of the myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases based on the application. The invention also provides application of the reagent for detecting the RSPO1 protein level in preparation of products for diagnosing cardiovascular diseases. According to the invention, the problem of insufficient adaptability and specificity of the existing marker is solved, RSPO1 is developed into a diagnostic marker, a DY4645-05 ELISA kit is adopted for detection and adaptation of multiple samples such as serum, multiple cardiovascular diseases can be diagnosed, cross-species application is realized, a basic research and clinical diagnosis detection system is unified, and powerful support is provided for diagnosis and treatment of cardiovascular diseases.

The invention belongs to the technical field of biology, and particularly relates to a biomarker for colorectal cancer diagnosis and application of the biomarker. Researches prove that the STAM2 gene is abnormally highly expressed in colorectal cancer cells or tissues. In-vitro function experiments show that the proliferation capacity of colorectal cancer cells can be inhibited by inhibiting the expression level of STAM2. Meanwhile, the growth of mouse colorectal cancer tumors can be inhibited by inhibiting the expression of the STAM2. The results jointly show that the STAM2 can be used as a novel diagnostic biomarker of the colorectal cancer, is beneficial to early screening and early diagnosis of the colorectal cancer, and improves the screening detection rate of the colorectal cancer, so that early intervention and early treatment are realized, the survival rate of the colorectal cancer is improved, and prognosis is improved.

The application belongs to the technical field of molecular diagnosis, and particularly relates to extracellular vesicle lncRNA as a molecular marker for diagnosing heart failure combined with dilated cardiomyopathy. The molecular marker is NR_045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is shown in SEQ ID NO. 5. The technical scheme provided by the application effectively improves the detection accuracy of heart failure combined with dilated cardiomyopathy. The P value of the combination of the molecular marker is less than 0.05, the |log fold change (FC)| is greater than 1, and the molecular marker has obvious differential expression relative to a healthy control group.

The application belongs to the technical field of biomarkers, and particularly relates to a marker for unexplained recurrent spontaneous abortion and application thereof. The marker is at least one of LARP1, LSM1 and NCBP2. The application has the advantages that in URSA, the expression of 6 m7G regulatory factors is abnormal: LSM1 and NUDT16 are up-regulated, and IFIT5, LARP1, NCBP2 and NUDT4 are down-regulated (P<0.05). Machine learning determines that LSM1, LARP1 and NCBP2 are high-performance diagnostic biomarkers, and the diagnostic value thereof is verified by qRT-PCR and immunofluorescence in independent samples.

The invention discloses application of a CCDC78 gene, relates to application of a gene, and provides application of the CCDC78 gene as a diagnosis marker, a prognosis evaluation marker and a treatment target of colon cancer in order to solve the problems that a CCDC78 mechanism is unknown and application of a single gene is deleted in the prior art. The expression inhibitor of the CCDC78 gene is used for preparing medicines for treating colon cancer. According to the application, by integrating multi-omics analysis and functional experiments, the dual value of the CCDC78 as an independent prognostic marker and a targeted therapy target is established, the mechanism that the CCDC78 possibly drives the progress of colon adenocarcinoma (COAD) by regulating a CDKN1A-CDK4 / E2F1 signal axis is disclosed, and the limitation that the CCDC78 mechanism is unknown and single gene application is deleted in the prior art is broken through. The method is applied to the technical field of biomedicine.

The invention belongs to the technical field of prostate cancer diagnosis, and particularly relates to serum 7-dehydrocholesterol as a prostate cancer metastasis and endocrine treatment drug resistance diagnosis marker and application thereof. 7-dehydrocholesterol provided by the invention has different levels in human prostate cancer cell lines such as LNCaP, Du145, PC3 and the like, and is abnormally increased in PC3, so that the 7-dehydrocholesterol can be used as a drug resistance diagnosis marker for prostate cancer metastasis and endocrine therapy; the reagent composition capable of specifically recognizing 7-dehydrocholesterol and generating detectable signals can be used for preparing a prostate cancer detection kit; the 7-dehydrocholesterol provided by the invention has non-invasive, non-invasive and efficient effects as a diagnostic marker, and solves the technical problem of lack of a prostate cancer diagnostic marker in the prior art.

The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof, and more particularly, to the epitope, and an antibody or an antigen-binding fragment binding thereto. The epitope region of the human Trx1 antigen confirmed in the present invention may be effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is effective in improvement of performance of a breast cancer diagnosis kit due to excellent binding affinity for Trx1 and very high sensitivity and specificity, compared to a conventional anti-Trx1 antibody. Further, the accuracy and reliability of breast cancer diagnosis may significantly increase because exceptionally high sensitivity and specificity are exhibited by detecting the monoclonal antibody of the present invention, which specifically binds to Trx1, rather than detecting CA15-3, another conventional breast cancer diagnostic biomarker.